[go: up one dir, main page]

Wu et al., 2014 - Google Patents

Conformation-dependent antibodies as tools for characterization of amyloid protein aggregates

Wu et al., 2014

Document ID
6186909990860699336
Author
Wu J
Breydo L
Publication year
Publication venue
Bio-nanoimaging

External Links

Snippet

Misfolding and aggregation of proteins plays an important role in many biologic processes and disease states. In order to unravel the precise causative relationship between the structure of protein aggregates and disease pathogenesis, detailed characterization of …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Similar Documents

Publication Publication Date Title
US20230295283A1 (en) N-terminal truncated protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's
TWI516500B (en) Monoclonal anti-beta-amyloid antibody
US9221900B2 (en) Methods for identifying safe and functional humanized antibodies
JP6190113B2 (en) Oligomer-specific amyloid beta epitopes and antibodies
US10035847B2 (en) Amyloid protofibril antibodies and methods of use thereof
JP7002811B2 (en) Anti-pyroglutamic acid oxidized amyloid β humanized antibody
Velasco et al. Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies
Lambracht-Washington et al. Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease
JP2006508072A (en) Amyloid beta-derived diffusible ligands (ADDLs), ADDL substitutes, ADDL-binding molecules, and uses thereof
TW201420602A (en) Monoclonal antibody
TW201206479A (en) Immunotherapy regimes dependent on ApoE status
Watanabe-Nakayama et al. Structural dynamics of amyloid-β protofibrils and actions of anti-amyloid-β antibodies as observed by high-speed atomic force microscopy
Chen et al. Computational investigation of gantenerumab and crenezumab recognition of Aβ fibrils in Alzheimer’s disease brain tissue
Foley et al. A focused chiral mutant library of the amyloid β 42 central electrostatic cluster as a tool to stabilize aggregation intermediates
Silverman et al. A rational structured epitope defines a distinct subclass of toxic amyloid-beta oligomers
Goñi et al. Production of monoclonal antibodies to pathologic β-sheet oligomeric conformers in neurodegenerative diseases
Akasaka et al. In vivo near-infrared fluorescence imaging selective for soluble amyloid β aggregates using y-shaped BODIPY derivative
Kreutzer et al. Antibodies raised against an Aβ oligomer mimic recognize pathological features in Alzheimer’s disease and associated amyloid-disease brain tissue
Tai et al. The tau oligomer antibody APNmAb005 detects early-stage pathological tau enriched at synapses and rescues neuronal loss in long-term treatments
Haynes et al. Targeting soluble amyloid-beta oligomers with a novel nanobody
Wu et al. Conformation-dependent antibodies as tools for characterization of amyloid protein aggregates
Jang et al. EPR Studies of Aβ42 Oligomers Indicate a Parallel In-Register β-Sheet Structure
Rahman Amyloid aggregates: detection and interaction
Zaccagnini In silico and in vitro screening of acridine and phenothiazine derivatives as anti-prion agents
HK1185797A (en) Safe and functional humanized antibodies